Ghost Tree Capital, LLC historic quarter change: USA Options, New
In put and call options, at their filed underlying value (listed in the US), over 14 quarters from 2013-12-31 to 2024-09-30, Ghost Tree Capital, LLC opened 86 positions, added to 10, reduced 5 and sold out of 79.
- Q3 2024: Stock XBI; Country of operation —; Class S&P BIOTECH · Put; Shares before 0.
- Q3 2024: Stock CRBP; Country of operation United States; Class COM NEW · Put; Shares before 0.
- Q2 2024: Stock ALNY; Country of operation United States; Class COM · Put; Shares before 0.
- Q2 2024: Stock INSM; Country of operation United States; Class COM PAR $.01 · Call; Shares before 0.
Each consecutive pair of Form 13F-HR filings compared (SEC CIK 1595851), 14 quarters: Q3 2024 (2024-06-30 to 2024-09-30, filed 2024-11-14); Q2 2024 (2024-03-31 to 2024-06-30, filed 2024-08-14); Q1 2024 (2023-12-31 to 2024-03-31, filed 2024-05-15); Q3 2016 (2016-06-30 to 2016-09-30, filed 2016-11-14); Q2 2016 (2016-03-31 to 2016-06-30, filed 2016-08-12); Q1 2016 (2015-12-31 to 2016-03-31, filed 2016-05-16); Q4 2015 (2015-09-30 to 2015-12-31, filed 2016-02-17); Q3 2015 (2015-06-30 to 2015-09-30, filed 2015-11-16); Q2 2015 (2015-03-31 to 2015-06-30, filed 2015-09-09); Q1 2015 (2014-12-31 to 2015-03-31, filed 2015-05-15); Q4 2014 (2014-09-30 to 2014-12-31, filed 2015-02-18); Q3 2014 (2014-06-30 to 2014-09-30, filed 2014-11-14); Q2 2014 (2014-03-31 to 2014-06-30, filed 2014-08-14); Q1 2014 (2013-12-31 to 2014-03-31, filed 2014-05-15). Rows for the same security, class and put/call are added together. Value change is the filed value at each quarter end, so it includes the price move. Only the filings held here are compared; the firm's 13F-HR filings go back to the quarter ended 2013-12-31. Not compared, as a quarter between them is not held here yet: 2016-09-30 to 2023-12-31 (missing 2016-12-31, 2017-03-31, 2017-06-30, 2017-09-30, 2017-12-31, 2018-03-31, 2018-06-30, 2018-09-30, 2018-12-31, 2019-03-31, 2019-06-30, 2019-09-30, 2019-12-31, 2020-03-31, 2020-06-30, 2020-09-30, 2020-12-31, 2021-03-31, 2021-06-30, 2021-09-30, 2021-12-31, 2022-03-31, 2022-06-30, 2022-09-30, 2022-12-31, 2023-03-31, 2023-06-30, 2023-09-30).
| Quarter | Stock | Country of operation | Class | Shares before | Shares after | Share change | Value before | Value after | Value change | Filed |
|---|
| Q3 2024 | XBI
SPDR SER TR | | S&P BIOTECH · Put | 0 | 300,000 | +300,000 | $0 | $29,640,000 | +$29,640,000 | 2024-11-14 |
|---|
| Q3 2024 | CRBP
CORBUS PHARMACEUTICALS HLDGS | United States | COM NEW · Put | 0 | 220,000 | +220,000 | $0 | $4,538,600 | +$4,538,600 | 2024-11-14 |
|---|
| Q2 2024 | ALNY
ALNYLAM PHARMACEUTICALS INC | United States | COM · Put | 0 | 68,400 | +68,400 | $0 | $16,621,200 | +$16,621,200 | 2024-08-14 |
|---|
| Q2 2024 | INSM
INSMED INC | United States | COM PAR $.01 · Call | 0 | 200,000 | +200,000 | $0 | $13,400,000 | +$13,400,000 | 2024-08-14 |
|---|
| Q2 2024 | ANNX
ANNEXON INC | United States | COM · Call | 0 | 214,500 | +214,500 | $0 | $1,051,050 | +$1,051,050 | 2024-08-14 |
|---|
| Q1 2024 | VKTX
VIKING THERAPEUTICS INC | United States | COM · Call | 0 | 80,000 | +80,000 | $0 | $6,560,000 | +$6,560,000 | 2024-05-15 |
|---|
| Q1 2024 | IMVT
IMMUNOVANT INC | United States | COM · Call | 0 | 150,000 | +150,000 | $0 | $4,846,500 | +$4,846,500 | 2024-05-15 |
|---|
| Q1 2024 | ACAD
ACADIA PHARMACEUTICALS INC | United States | COM · Call | 0 | 200,000 | +200,000 | $0 | $3,698,000 | +$3,698,000 | 2024-05-15 |
|---|
| Q1 2024 | INTRA-CELLULAR THERAPIES INC
CUSIP 46116X101 | United States | COM · Call | 0 | 50,000 | +50,000 | $0 | $3,460,000 | +$3,460,000 | 2024-05-15 |
|---|
| Q1 2024 | RAPT THERAPEUTICS INC
CUSIP 75382E109 | United States | COM · Call | 0 | 300,000 | +300,000 | $0 | $2,694,000 | +$2,694,000 | 2024-05-15 |
|---|
| Q3 2016 | IBB
ISHARES TR | | NASDQ BIOTEC ETF · Put | 0 | 100,000 | +100,000 | $0 | $28,946,000 | +$28,946,000 | 2016-11-14 |
|---|
| Q3 2016 | BIIB
BIOGEN INC | United States | COM · Call | 0 | 65,000 | +65,000 | $0 | $20,347,000 | +$20,347,000 | 2016-11-14 |
|---|
| Q3 2016 | AERIE PHARMACEUTICALS INC
CUSIP 00771V108 | | COM · Call | 0 | 300,000 | +300,000 | $0 | $11,322,000 | +$11,322,000 | 2016-11-14 |
|---|
| Q3 2016 | BMY
BRISTOL MYERS SQUIBB CO | United States | COM · Call | 0 | 200,000 | +200,000 | $0 | $10,784,000 | +$10,784,000 | 2016-11-14 |
|---|
| Q3 2016 | MRK
MERCK & CO INC | United States | COM · Call | 0 | 150,000 | +150,000 | $0 | $9,362,000 | +$9,362,000 | 2016-11-14 |
|---|
| Q3 2016 | OPHTHOTECH CORP
CUSIP 683745103 | | COM · Call | 0 | 200,000 | +200,000 | $0 | $9,226,000 | +$9,226,000 | 2016-11-14 |
|---|
| Q3 2016 | CELGENE CORP
CUSIP 151020104 | | COM · Call | 0 | 75,000 | +75,000 | $0 | $7,840,000 | +$7,840,000 | 2016-11-14 |
|---|
| Q3 2016 | IONS
IONIS PHARMACEUTICALS INC | United States | COM · Call | 0 | 150,000 | +150,000 | $0 | $5,496,000 | +$5,496,000 | 2016-11-14 |
|---|
| Q3 2016 | KITE PHARMA INC
CUSIP 49803L109 | | COM · Call | 0 | 65,000 | +65,000 | $0 | $3,631,000 | +$3,631,000 | 2016-11-14 |
|---|
| Q3 2016 | CYH
COMMUNITY HEALTH SYS INC NEW | United States | COM · Call | 0 | 250,000 | +250,000 | $0 | $2,885,000 | +$2,885,000 | 2016-11-14 |
|---|
| Q3 2016 | DVAX
DYNAVAX TECHNOLOGIES CORP | United States | COM NEW · Call | 0 | 200,000 | +200,000 | $0 | $2,098,000 | +$2,098,000 | 2016-11-14 |
|---|
| Q3 2016 | OPHTHOTECH CORP
CUSIP 683745103 | | COM · Put | 0 | 43,600 | +43,600 | $0 | $2,011,000 | +$2,011,000 | 2016-11-14 |
|---|
| Q3 2016 | ARIAD PHARMACEUTICALS INC
CUSIP 04033A100 | | COM · Put | 0 | 100,000 | +100,000 | $0 | $1,369,000 | +$1,369,000 | 2016-11-14 |
|---|
| Q3 2016 | NOVAVAX INC
CUSIP 670002104 | | COM · Call | 0 | 400,000 | +400,000 | $0 | $832,000 | +$832,000 | 2016-11-14 |
|---|
| Q3 2016 | NOVAVAX INC
CUSIP 670002104 | | COM · Put | 0 | 200,000 | +200,000 | $0 | $416,000 | +$416,000 | 2016-11-14 |
|---|
| Q3 2016 | INOTEK PHARMACEUTICALS CORP
CUSIP 45780V102 | | COM · Call | 0 | 20,700 | +20,700 | $0 | $196,000 | +$196,000 | 2016-11-14 |
|---|
| Q2 2016 | SPY
SPDR S&P 500 ETF TR | | TR UNIT · Put | 0 | 100,000 | +100,000 | $0 | $20,948,000 | +$20,948,000 | 2016-08-12 |
|---|
| Q2 2016 | BSX
BOSTON SCIENTIFIC CORP | United States | COM · Call | 0 | 350,000 | +350,000 | $0 | $8,180,000 | +$8,180,000 | 2016-08-12 |
|---|
| Q2 2016 | CLOVIS ONCOLOGY INC
CUSIP 189464100 | | COM · Put | 0 | 500,000 | +500,000 | $0 | $6,860,000 | +$6,860,000 | 2016-08-12 |
|---|
| Q2 2016 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM · Put | 0 | 300,000 | +300,000 | $0 | $5,721,000 | +$5,721,000 | 2016-08-12 |
|---|
| Q2 2016 | INTERCEPT PHARMACEUTICALS IN
CUSIP 45845P108 | United States | COM · Call | 0 | 35,000 | +35,000 | $0 | $4,994,000 | +$4,994,000 | 2016-08-12 |
|---|
| Q2 2016 | SAGE THERAPEUTICS INC
CUSIP 78667J108 | United States | COM · Call | 0 | 150,000 | +150,000 | $0 | $4,520,000 | +$4,520,000 | 2016-08-12 |
|---|
| Q2 2016 | TESARO INC
CUSIP 881569107 | | COM · Call | 0 | 50,000 | +50,000 | $0 | $4,203,000 | +$4,203,000 | 2016-08-12 |
|---|
| Q2 2016 | HORIZON PHARMA PLC
CUSIP G4617B105 | | SHS · Call | 0 | 200,000 | +200,000 | $0 | $3,294,000 | +$3,294,000 | 2016-08-12 |
|---|
| Q2 2016 | SRPT
SAREPTA THERAPEUTICS INC | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $1,907,000 | +$1,907,000 | 2016-08-12 |
|---|
| Q2 2016 | IMMUNOMEDICS INC
CUSIP 452907108 | | COM · Call | 0 | 200,000 | +200,000 | $0 | $464,000 | +$464,000 | 2016-08-12 |
|---|
| Q1 2016 | XBI
SPDR SERIES TRUST | | S&P BIOTECH · Put | 0 | 220,000 | +220,000 | $0 | $11,037,000 | +$11,037,000 | 2016-05-16 |
|---|
| Q1 2016 | ACAD
ACADIA PHARMACEUTICALS INC | United States | COM · Put | 0 | 350,000 | +350,000 | $0 | $9,786,000 | +$9,786,000 | 2016-05-16 |
|---|
| Q1 2016 | EW
EDWARDS LIFESCIENCES CORP | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $8,821,000 | +$8,821,000 | 2016-05-16 |
|---|
| Q1 2016 | IWM
ISHARES TR | | RUSSELL 2000 ETF · Put | 0 | 75,000 | +75,000 | $0 | $8,297,000 | +$8,297,000 | 2016-05-16 |
|---|
| Q1 2016 | ABBV
ABBVIE INC | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $5,712,000 | +$5,712,000 | 2016-05-16 |
|---|
| Q1 2016 | VALEANT PHARMACEUTICALS INTL
CUSIP 91911K102 | | COM · Call | 0 | 100,000 | +100,000 | $0 | $2,630,000 | +$2,630,000 | 2016-05-16 |
|---|
| Q1 2016 | PORTOLA PHARMACEUTICALS INC
CUSIP 737010108 | | COM · Call | 0 | 100,000 | +100,000 | $0 | $2,040,000 | +$2,040,000 | 2016-05-16 |
|---|
| Q4 2015 | CLOVIS ONCOLOGY INC
CUSIP 189464100 | | COM · Call | 0 | 50,000 | +50,000 | $0 | $1,750,000 | +$1,750,000 | 2016-02-17 |
|---|
| Q4 2015 | FOLD
AMICUS THERAPEUTICS INC | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $970,000 | +$970,000 | 2016-02-17 |
|---|
| Q3 2015 | ALNYLAM PHARMACEUTICALS INC
CUSIP 02043Q907 | | COM · Call | 0 | 75,000 | +75,000 | $0 | $6,027,000 | +$6,027,000 | 2015-11-16 |
|---|
| Q3 2015 | BRISTOL MYERS SQUIBB CO
CUSIP 110122908 | | COM · Call | 0 | 100,000 | +100,000 | $0 | $5,920,000 | +$5,920,000 | 2015-11-16 |
|---|
| Q3 2015 | THERAPEUTICSMD INC
CUSIP 88338N907 | | COM · Call | 0 | 500,000 | +500,000 | $0 | $2,930,000 | +$2,930,000 | 2015-11-16 |
|---|
| Q3 2015 | HERON THERAPEUTICS INC
CUSIP 427746902 | | COM · Call | 0 | 100,000 | +100,000 | $0 | $2,440,000 | +$2,440,000 | 2015-11-16 |
|---|
| Q3 2015 | PTC THERAPEUTICS INC
CUSIP 69366J900 | | COM · Call | 0 | 75,000 | +75,000 | $0 | $2,003,000 | +$2,003,000 | 2015-11-16 |
|---|
| Q3 2015 | BIODELIVERY SCIENCES INTL IN
CUSIP 09060J906 | | COM · Call | 0 | 106,200 | +106,200 | $0 | $590,000 | +$590,000 | 2015-11-16 |
|---|
| Q2 2015 | ROCKWELL MED INC
CUSIP 774374102 | | COM · Call | 0 | 200,000 | +200,000 | $0 | $3,224,000 | +$3,224,000 | 2015-09-09 |
|---|
| Q2 2015 | SAGE THERAPEUTICS INC
CUSIP 78667J108 | United States | COM · Call | 0 | 31,700 | +31,700 | $0 | $2,314,000 | +$2,314,000 | 2015-09-09 |
|---|
| Q1 2015 | XBI
SPDR SERIES TRUST | | S&P BIOTECH · Put | 0 | 100,000 | +100,000 | $0 | $22,550,000 | +$22,550,000 | 2015-05-15 |
|---|
| Q1 2015 | NUVASIVE INC
CUSIP 670704105 | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $4,599,000 | +$4,599,000 | 2015-05-15 |
|---|
| Q1 2015 | A
AGILENT TECHNOLOGIES INC | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $4,155,000 | +$4,155,000 | 2015-05-15 |
|---|
| Q1 2015 | AVALANCHE BIOTECHNOLOGIES IN
CUSIP 05337G107 | | COM · Call | 0 | 100,000 | +100,000 | $0 | $4,052,000 | +$4,052,000 | 2015-05-15 |
|---|
| Q1 2015 | BIODELIVERY SCIENCES INTL IN
CUSIP 09060J106 | | COM · Call | 0 | 200,000 | +200,000 | $0 | $2,100,000 | +$2,100,000 | 2015-05-15 |
|---|
| Q4 2014 | GILD
GILEAD SCIENCES INC | United States | COM · Call | 0 | 125,000 | +125,000 | $0 | $11,783,000 | +$11,783,000 | 2015-02-18 |
|---|
| Q4 2014 | SYK
STRYKER CORP | United States | COM · Call | 0 | 100,000 | +100,000 | $0 | $9,433,000 | +$9,433,000 | 2015-02-18 |
|---|
| Q4 2014 | ISIS PHARMACEUTICALS INC
CUSIP 464330109 | | COM · Call | 0 | 150,000 | +150,000 | $0 | $9,261,000 | +$9,261,000 | 2015-02-18 |
|---|
| Q4 2014 | ISIS PHARMACEUTICALS INC
CUSIP 464330109 | | COM · Put | 0 | 50,000 | +50,000 | $0 | $3,087,000 | +$3,087,000 | 2015-02-18 |
|---|
| Q4 2014 | ACHILLION PHARMACEUTICALS IN
CUSIP 00448Q201 | | COM · Call | 0 | 150,000 | +150,000 | $0 | $1,838,000 | +$1,838,000 | 2015-02-18 |
|---|
| Q3 2014 | BRISTOL MYERS SQUIBB CO
CUSIP 110122908 | | CALL · Call | 0 | 200,000 | +200,000 | $0 | $10,236,000 | +$10,236,000 | 2014-11-14 |
|---|
| Q3 2014 | VALEANT PHARMACEUTICALS INTL
CUSIP 91911K902 | | CALL · Call | 0 | 50,000 | +50,000 | $0 | $6,560,000 | +$6,560,000 | 2014-11-14 |
|---|
| Q3 2014 | ABBVIE INC
CUSIP 00287Y909 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $5,776,000 | +$5,776,000 | 2014-11-14 |
|---|
| Q3 2014 | AGILENT TECHNOLOGIES INC
CUSIP 00846U901 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $5,698,000 | +$5,698,000 | 2014-11-14 |
|---|
| Q3 2014 | CEPHEID
CUSIP 15670R907 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $4,403,000 | +$4,403,000 | 2014-11-14 |
|---|
| Q3 2014 | NEUROCRINE BIOSCIENCES INC
CUSIP 64125C909 | | CALL · Call | 0 | 200,000 | +200,000 | $0 | $3,134,000 | +$3,134,000 | 2014-11-14 |
|---|
| Q3 2014 | ALIMERA SCIENCES INC
CUSIP 016259103 | | COM · Put | 0 | 200,000 | +200,000 | $0 | $1,084,000 | +$1,084,000 | 2014-11-14 |
|---|
| Q3 2014 | VANDA PHARMACEUTICALS INC
CUSIP 921659908 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $1,038,000 | +$1,038,000 | 2014-11-14 |
|---|
| Q3 2014 | ALCOBRA LTD
CUSIP M2239P909 | | CALL · Call | 0 | 50,000 | +50,000 | $0 | $772,000 | +$772,000 | 2014-11-14 |
|---|
| Q3 2014 | CATALYST PHARM PARTNERS INC
CUSIP 14888U951 | | PUT · Put | 0 | 100,000 | +100,000 | $0 | $332,000 | +$332,000 | 2014-11-14 |
|---|
| Q2 2014 | SPDR S&P 500 ETF TR
CUSIP 78462F953 | | PUT · Put | 0 | 75,000 | +75,000 | $0 | $14,679,000 | +$14,679,000 | 2014-08-14 |
|---|
| Q2 2014 | BIODELIVERY SCIENCES INTL IN
CUSIP 09060J906 | | CALL · Call | 0 | 300,000 | +300,000 | $0 | $3,621,000 | +$3,621,000 | 2014-08-14 |
|---|
| Q2 2014 | DEPOMED INC
CUSIP 249908954 | | PUT · Put | 0 | 120,000 | +120,000 | $0 | $1,668,000 | +$1,668,000 | 2014-08-14 |
|---|
| Q2 2014 | NPS PHARMACEUTICALS INC
CUSIP 62936P903 | | CALL · Call | 0 | 50,000 | +50,000 | $0 | $1,653,000 | +$1,653,000 | 2014-08-14 |
|---|
| Q2 2014 | ACHILLION PHARMACEUTICALS IN
CUSIP 00448Q901 | | CALL · Call | 0 | 150,000 | +150,000 | $0 | $1,136,000 | +$1,136,000 | 2014-08-14 |
|---|
| Q2 2014 | INOVIO PHARMACEUTICALS INC
CUSIP 45773H951 | | PUT · Put | 0 | 100,000 | +100,000 | $0 | $1,081,000 | +$1,081,000 | 2014-08-14 |
|---|
| Q1 2014 | ISHARES
CUSIP 464287955 | | PUT · Put | 0 | 150,000 | +150,000 | $0 | $17,451,000 | +$17,451,000 | 2014-05-15 |
|---|
| Q1 2014 | MERCK & CO INC NEW
CUSIP 58933Y905 | | CALL · Call | 0 | 250,000 | +250,000 | $0 | $14,193,000 | +$14,193,000 | 2014-05-15 |
|---|
| Q1 2014 | BRISTOL MYERS SQUIBB CO
CUSIP 110122908 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $5,195,000 | +$5,195,000 | 2014-05-15 |
|---|
| Q1 2014 | MYLAN INC
CUSIP 628530907 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $4,883,000 | +$4,883,000 | 2014-05-15 |
|---|
| Q1 2014 | AEGERION PHARMACEUTICALS INC
CUSIP 00767E902 | | CALL · Call | 0 | 100,000 | +100,000 | $0 | $4,618,000 | +$4,618,000 | 2014-05-15 |
|---|
| Q1 2014 | INSMED INC
CUSIP 457669907 | | CALL · Call | 0 | 200,000 | +200,000 | $0 | $3,808,000 | +$3,808,000 | 2014-05-15 |
|---|
| Q1 2014 | CHELSEA THERAPEUTICS INTL LT
CUSIP 163428905 | | CALL · Call | 0 | 300,000 | +300,000 | $0 | $1,656,000 | +$1,656,000 | 2014-05-15 |
|---|